Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
This trial is active, not recruiting.
|Sponsor||Brigham and Women's Hospital|
|Collaborator||University of Utah|
|Start date||January 2007|
|End date||March 2017|
|Trial size||100 participants|
|Trial identifier||NCT01009944, 2007p002290|
The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.
|Intervention model||single group assignment|
One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
time frame: 16 weeks
Male or female participants from 18 years up to 65 years old.
Inclusion Criteria: - Male and female hypertensive participants who were previously studied in SCOR program. Exclusion Criteria: - Diabetes - Taking other medications beside thyroid or estrogen supplements.
|Official title||Genetic Mechanisms in Human Hypertension RAAS Inhibition Study|
|Principal investigator||Gordon H. Williams, MD|
Call for more information